Aptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast, 2024 – 2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast, 2024 – 2032
Aptamers Market Size
Aptamers Market size accounted for USD 2.9 billion in 2023 and is estimated to grow at 20.3% to reach USD 15.1 billion by 2032. Distinct advantages that aptamers offer over traditional antibodies are driving the rapid development of the industry.
Aptamers, with their unique characteristics of high specificity and affinity for target molecules, are poised to revolutionize various industries, particularly in healthcare and biotechnology. Also, unlike antibodies, aptamers can be easily synthesized and chemically modified, enabling swift optimization for specific applications. This scalability ensures efficient and cost-effective production, expediting research and development processes. Moreover, aptamers' small size, low immunogenicity, and ease of customization result in enhanced target binding and reduced off-target effects.
Aptamers are short, single-stranded DNA, RNA, or peptide molecules that are selected from large libraries of random sequences through a process known as systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have a unique three-dimensional structure that allows them to specifically bind to target molecules, such as proteins, nucleic acids, small molecules, or cells, with high affinity and selectivity.
| Report Attribute | Details |
|---|---|
| Base Year | 2023 |
| Aptamers Market Size in 2023 | USD 2.9 Billion |
| Forecast Period | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR | 20% |
| 2032 Value Projection | USD 15.1 Billion |
| Historical Data for | 2018 to 2023 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 262 |
| Segments covered | Type, Application, Technology, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The emergence of the COVID-19 pandemic had a positive impact on aptamers market. As the global healthcare group rapidly responded to the urgent need for diagnostic tools and therapeutics, aptamers emerged as a versatile solution. Their ability to bind to specific targets enabled the development of rapid and sensitive diagnostic assays, swiftly and accurately for detecting the virus. Moreover, aptamers have also demonstrated potential in neutralizing the virus by inhibiting its interaction with human cells. This newfound application potential has attracted substantial research funding and collaboration from both public and private sectors.
Aptamers Market Trends
The rise in chronic and rare diseases is like a wake-up call for the healthcare industry. It's a call to action to find innovative ways to help people who are living with these conditions. Take cancer, for example. In the United States alone, almost 2 million people were diagnosed with cancer in 2022, and sadly, over 600,000 people died from it. These numbers are staggering, and they show that we need better treatments, and we need them fast. Aptamers can provide a solution, like a key that unlocks a door to more precise treatments. They can be designed to target specific molecules that are unique to each type of disease. This means that aptamers can help us develop treatments that are tailored to each individual patient. Another advantage of aptamers is their versatilitythey can be used to target a wide range of diseases. This means that they could be used to develop treatments for many different types of cancer, as well as other chronic and rare diseases.
Aptamers Restraint
The aptamers market faces a significant challenge due to the low awareness levels and incomplete regulatory policies. Despite their immense potential, aptamers remain relatively lesser known compared to other biotechnologies. This lack of awareness among healthcare professionals, researchers, and potential end-users can impede the industry expansion by limiting adoption and investment. Moreover, the absence of comprehensive and well-established regulatory frameworks specifically tailored for aptamers can introduce uncertainty and hurdles in their development and commercialization processes. Also, the evolving nature of aptamer technology often falls outside the scope of traditional regulations, leading to inconsistencies and delays in approvals.
Aptamers Market Analysis
By type, the aptamers market is classified into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The DNA-based aptamers segment accounted for 63.4% of the industry share in 2022. DNA-based aptamers, derived from DNA sequences, offer a versatile and well-established platform for a wide array of applications. Their unique characteristics, such as stability, cost-effectiveness, and ease of synthesis, have increased their demand in healthcare industry. Furthermore, recent progress in the development, purification, and targeted delivery of aptamers to eliminate specific cells has captured the interest of numerous researchers.
When it comes to using aptamers, different fields like research, testing for diseases, making drugs, and more, have their own needs. In 2022, the research and development group took the biggest slice of the market, at 35.6%. Aptamers have become a go-to tool for R&D because they are versatile and can be tailored to meet specific requirements. This has caught the attention of both universities and businesses, who are working together to push the boundaries of aptamer innovation. They are also making progress in how they find and change aptamers. For example, in June 2021, SomaLogic joined forces with Ixaka Ltd to find and make aptamer-based drugs that can target two different things at once.
Based on technology, the aptamers market is segmented into SELEX, X-aptamers, and other technologies. The SELEX segment is projected to witness significant progressF of 19.9% by 2032. SELEX's unique capability to systematically identify high-affinity aptamers for diverse targets offers a strategic advantage in the development of aptamer-based solutions. Also, SELEX involves a methodical process of selection, amplification, and refinement, empowering researchers to craft aptamers for precise binding. Moreover, the continuous enhancements in SELEX methodologies coupled with SELEX's role in enabling the creation of innovative diagnostics, therapeutics, and research tools has fuelled its widespread adoption.
Based on end-use, the aptamers market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, research institutes, and other end-users. The pharmaceutical & biotechnology companies segment is projected to witness significant growth of 20.3% by 2032. Increasing investments in pharmaceutical research & development will significantly drive the aptamer industry by catalysing innovation and accelerating the development of aptamer-based solutions. For instance, in June 2018, Aptamer Group Ltd received USD 2.2 million from Meneldor, a biopharmaceutical investment company and other overseas investors. This fund was utilized to drive preclinical discovery programs involving the development of aptamer drug conjugates.
North America aptamers market accounted for 43.6% industry share in 2022. The region's well-established pharmaceutical and biotechnology industry, along with the presence of prominent research institutes, academic centers, and well-funded healthcare initiatives. Moreover, the growing prevalence of chronic diseases such as cancer, cardiovascular disease (CVD) and age-related macular degeneration (AMD). Additionally, the region's proactive regulatory landscape and supportive policies facilitate efficient development, validation, and commercialization of aptamer-based products.
Aptamers Market Share
Major industry players operating in the aptamers market include
- SomaLogic
- Aptamer Group
- Aptadel Therapeutics
- Base Pair Biotechnologies
- Vivonics Inc.
Aptamers Industry News
- In January 2023, Aptamer Group partnered with BaseCure Therapeutics to develop new targeted gene therapies. This partnership helps to identify specific cell types that might be developed as potential delivery vehicles for siRNA uptake into target cells and tissues. This strategy helped the company to create new opportunities for the expansion of aptamer applications in the field of therapeutics.
- In June 2021, Ixaka Ltd collaborated with SomaLogic to support the development of aptamer-based bispecific therapeutics. The collaboration evaluated the safety and efficacy of antigen specific SOMAmer reagents previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamer. This strategy helped the company to enhance its aptamer-based bispecific therapeutics.
The aptamers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Type
- DNA-based aptamers
- RNA-based aptamers
- XNA-based aptamers
By Application
- Research & development
- Diagnostics
- Therapeutics
- Other applications
By Technology
- SELEX
- X-aptamers
- Other technologies
By End-use
- Pharmaceutical & biotechnology companies
- Academic & government research institutes
- CROs
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy